A bottle of Botox. The drug used for wrinkles has now been approved as a treatment for overactive bladders.(Photo: Handout)
USA TODAY - Allergan CEO David Pyott's 2012 compensation, including stock gains, jumped more than 35% to $57.7 million, according to a preliminary proxy filed Friday.
Pyott received pay, stock, stock options and other compensation valued at about $21 million, gained $36.6 million exercising stock options and another $2.8 million from vested shares. That's up from $42.5 million in 2011, including stock option gains valued at $30.6 million.
Allergan, perhaps best known for anti-wrinkle drug Botox, named Pyott CEO in 1998.
As part of his 2012 compensation package, Pyott, 59, received a special performance-based "recognition and retention" stock award valued at $9.4 million that vests in 2017, stock options valued at $7 million, $1.6 million as a bonus performance award and $1.3 million in salary.
(Copyright © 2013 USA TODAY)